医疗服务版图再扩张 盈康生命收购长沙珂信51%股权

Core Viewpoint - Yingkang Life plans to acquire 51% equity of Changsha Kexin Oncology Hospital for 357 million yuan, marking a significant step in its regional medical center layout and "1+n" strategy [1][2] Group 1: Acquisition Details - The acquisition amount is 357 million yuan, and after the transaction, Changsha Kexin will become a subsidiary of Yingkang Life, included in the consolidated financial statements [1] - The acquisition aims to strengthen the company's oncology specialty in medical services, enhance performance, and achieve sustainable operational capabilities [1][2] Group 2: Financial Performance and Projections - Changsha Kexin reported revenues of 273 million yuan and a net profit of approximately 33.43 million yuan for the first three quarters of 2024 [2] - The agreement stipulates that Changsha Kexin's net profits for 2025, 2026, and 2027 will not be less than 57 million yuan, 58 million yuan, and 60 million yuan, respectively [2] Group 3: Operational Strengths - Changsha Kexin is equipped with advanced medical technology, including the second Varian Halcyon linear accelerator in China, and has established a tumor MDT consultation platform for personalized treatment [2] - The company is advancing its external growth strategy through acquisitions and operational management, aiming to create a standardized process for project acquisitions and management [2]